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Background: Light transmittance aggregometry (LTA) is a widely used method to determine platelet function during antiplatelet therapy but has 
been criticized for intra-assay variability. However, the coefficient of variation with LTA has never been reported in a large study. VerifyNow is a widely 
used, FDA approved point-of-care (POC) assay with a reported coefficient of variation approx. 7% (package insert, Accumetrics, Inc). We sought to 
establish the intra-assay variation of ADP-induced aggregation measured by LTA from a high volume platelet research center.
methods: Data was compiled from stable coronary artery disease patients enrolled in the RESPOND STUDY at the Sinai Center for Thrombosis 
Research. 20 µmol/L ADP-induced platelet aggregation in platelet rich plasma was assessed in duplicate with a Chronolog Optical Aggregometer 
(model 490-4D) at various times pre- and post-ticagrelor or clopidogrel administration on a background of aspirin therapy. Aggregation was 
expressed as the maximum and final (6 minutes) percent change in light transmittance from baseline with platelet-poor plasma as a reference.
results: There were 752 samples run in duplicate, for a total of 3,008 aggregation values (range, 0-96%). The mean +/- SD for maximum and 
final aggregation were 44.5+/-3.5% and 27.0+/-3.4% respectively. The coefficient of variation was 7.7% and 12.5% for maximum and final platelet 
aggregation, respectively.
conclusion: To our knowledge this is the largest study of intra-assay variability for LTA. Maximum aggregation is less variable than final and is 
comparable to the variability reported for the most widely used POC analyzer, VerifyNow. These data demonstrate that LTA remains a valuable method 
to assess the pharmacodynamic effects of antiplatelet therapy when conducted in a high-volume research center.
